Supplementary MaterialsSupplementary information 41598_2019_52714_MOESM1_ESM

Supplementary MaterialsSupplementary information 41598_2019_52714_MOESM1_ESM. suggest that the combination of HDACi and BRD4i should be pursued in further pre-clinical testing. expression could be a potential target for therapy in lymphomas. Indeed, BCL6 inhibition using specific inhibitors was able to produce apoptosis and cell cycle arrest of these cells10, 11 suggesting that…